Literature DB >> 12018920

Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease.

Kerstin Röhss1, Göran Hasselgren, Hans Hedenström.   

Abstract

Maintenance of intragastric pH > 4 is vital for effective management of gastroesophageal reflux disease (GERD). Esomeprazole 40 mg, the first proton pump inhibitor developed as an optical isomer, demonstrates improved acid inhibition over omeprazole 20 mg. Our aim was to compare esomeprazole 40 mg with omeprazole 40 mg, once-daily, on intragastric acidity in patients with symptoms of GERD. In this open-label, crossover study, 130 patients with symptoms of GERD received esomeprazole 40 mg or omeprazole 40 mg once-daily for five days. The 24-hr intragastric pH was monitored on days 1 and 5 of each treatment period. The mean percentage of the 24-hr period with intragastric pH > 4 was significantly greater (P < 0.001) with esomeprazole 40 mg than with omeprazole 40 mg on days 1 (48.6% vs 40.6%) and 5 (68.4% vs 62.0%). Interpatient variability was significantly less with esomeprazole than omeprazole. Esomeprazole was well tolerated. In conclusion, esomeprazole 40 mg provides more effective acid control than twice the standard dose of omeprazole.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12018920     DOI: 10.1023/a:1015009300955

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  14 in total

1.  An evidence-based appraisal of reflux disease management--the Genval Workshop Report.

Authors: 
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

2.  Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis.

Authors:  N Chiba; C J De Gara; J M Wilkinson; R H Hunt
Journal:  Gastroenterology       Date:  1997-06       Impact factor: 22.682

3.  Prolonged pH recording in the study of gastro-oesophageal reflux.

Authors:  J Spencer
Journal:  Br J Surg       Date:  1969-12       Impact factor: 6.939

4.  Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease.

Authors:  T Lind; L Rydberg; A Kylebäck; A Jonsson; T Andersson; G Hasselgren; J Holmberg; K Röhss
Journal:  Aliment Pharmacol Ther       Date:  2000-07       Impact factor: 8.171

5.  Ambulatory 24-hour pH-metry in the diagnosis of gastroesophageal reflux disease. Determination of criteria and relation to endoscopy.

Authors:  A A Masclee; A C de Best; R de Graaf; O J Cluysenaer; J B Jansen
Journal:  Scand J Gastroenterol       Date:  1990-03       Impact factor: 2.423

6.  Heartburn--the acid test.

Authors:  B Joelsson; F Johnsson
Journal:  Gut       Date:  1989-11       Impact factor: 23.059

7.  Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators.

Authors:  P J Kahrilas; G W Falk; D A Johnson; C Schmitt; D W Collins; J Whipple; D D'Amico; B Hamelin; B Joelsson
Journal:  Aliment Pharmacol Ther       Date:  2000-10       Impact factor: 8.171

8.  Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.

Authors:  J E Richter; P J Kahrilas; J Johanson; P Maton; J R Breiter; C Hwang; V Marino; B Hamelin; J G Levine
Journal:  Am J Gastroenterol       Date:  2001-03       Impact factor: 10.864

9.  Development of the 24-hour intraesophageal pH monitoring composite scoring system.

Authors:  L F Johnson; T R DeMeester
Journal:  J Clin Gastroenterol       Date:  1986       Impact factor: 3.062

10.  Appropriate acid suppression for the management of gastro-oesophageal reflux disease.

Authors:  N J Bell; D Burget; C W Howden; J Wilkinson; R H Hunt
Journal:  Digestion       Date:  1992       Impact factor: 3.216

View more
  22 in total

Review 1.  What is potent acid inhibition, and how can it be achieved?

Authors:  Xavier Calvet; Fernando Gomollón
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis.

Authors:  Colleen Schmitt; Charles J Lightdale; Clara Hwang; Bernard Hamelin
Journal:  Dig Dis Sci       Date:  2006-04-27       Impact factor: 3.199

3.  Inhibition of pentagastrin-stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults.

Authors:  Vijaya S Pratha; Daniel L Hogan; James R Lane; Paul J Williams; Michael S Burton; Richard B Lynn; Robyn G Karlstadt
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

4.  Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism.

Authors:  Horng-Yuan Lou; Chun-Chao Chang; Ming-Thau Sheu; Ying-Chen Chen; Hsiu-O Ho
Journal:  Eur J Clin Pharmacol       Date:  2008-08-27       Impact factor: 2.953

Review 5.  Clinical response (remission of symptoms) in erosive and non-erosive gastro-oesophageal reflux disease.

Authors:  J Enrique Domínguez-Muñoz; Miguel Sobrino
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 6.  Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know.

Authors:  Malcolm Robinson; John Horn
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 7.  Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults.

Authors:  Kate McKeage; Stephanie K A Blick; Jamie D Croxtall; Katherine A Lyseng-Williamson; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.

Authors:  Kerstin Röhss; Tore Lind; Clive Wilder-Smith
Journal:  Eur J Clin Pharmacol       Date:  2004-09-02       Impact factor: 2.953

Review 9.  Gastric function measurements in drug development.

Authors:  Thorsten Pohle; Wolfram Domschke
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

Review 10.  Esomeprazole: a review of its use in the management of acid-related disorders.

Authors:  Lesley J Scott; Christopher J Dunn; Gordon Mallarkey; Miriam Sharpe
Journal:  Drugs       Date:  2002       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.